Rxrx stock forecast.

Recursion Pharmaceuticals (RXRX 7.88%) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug ...

Rxrx stock forecast. Things To Know About Rxrx stock forecast.

Recursion Pharmaceuticals Inc. 7.06. Delayed Data. As of Nov 17. +0.39 / +5.85%. Today’s Change. 4.54. Today ||| 52-Week Range. 16.75.Dec 4, 2023 · The company, currently valued at $1.60B, closed the last trade at $7.39 per share which meant it gained $0.54 on the day or 7.88% during that session. The RXRX stock price is -126.66% off its 52-week high price of $16.75 and 38.57% above the 52-week low of $4.54. If we look at the company’s 10-day average daily trading volume, we find that it ... Recursion Pharma may be a biotech stock, but it scored a $50 million investment from Nvidia to fund its AI technology in mid-July - making NVDA a significant stakeholder in RXRX. The partnership ...Analysts on Wall Street sometimes assign one-year price targets to stocks that imply massive upside potential. That's what's happening with Recursion …

The 7 analysts offering 1 year price forecasts for RXRX have a max estimate of — and a min estimate of —. Analyst rating Based on 7 analysts giving stock ratings to RXRX in the past 3 months.

Nov 28, 2023 · According to 6 stock analysts, the average 12-month stock price forecast for RXRX stock stock is $15.33, which predicts an increase of 120.26%. The lowest target is $8.00 and the highest is $33. On average, analysts rate RXRX stock stock as a buy.

Recursion Pharmaceuticals Inc Cl A stocks price quote with latest real-time prices, charts, financials, ... RXRX Related stocks. Symbol 3M %Chg ; RXRX -18.97% : Recursion Pharmaceuticals Inc Cl A: ZTS -6.96% : Zoetis Inc Cl A: TAK ... Cash Markets Overview Corn Indexes Soybean Indexes Yield Forecast Indexes.If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Recursion Pharmaceuticals Inc. research and ratings by Barron's. View RXRX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.At the close of trading, the stock’s price was $5.09, to imply a decrease of -3.60% or -$0.19 in intraday trading. The RXRX share’s 52-week high remains $16.75, putting it -229.08% down since that peak but still an impressive 10.81% since price per share fell to its 52-week low of $4.54.

The US$14.13 analyst price target for RXRX is 3.5% less than our ... we will estimate the stock's intrinsic value by taking the forecast future cash flows of the company and discounting ...

Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...

(See RXRX stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy , a newly launched tool that unites all of TipRanks’ equity insights.That’s as shares of Recursion Pharmaceuticals RXRX are exploding higher on the day. In fact, RXRX stock is currently up about 17% so far in the session. Butterfly with parabolic D leg action. This looks like classic D leg stuff. All parabolic action, few pullbacks and getting a lot of public attention. In the last three months, insiders have sold 333,493 shares of company stock worth $2,375,196. 19.96% of the stock is currently owned by insiders. Wall Street Analysts Forecast GrowthSee the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report. Omega Therapeutics, Inc. (OMGA) : Free Stock Analysis Report ... according to the forecast. 7h ago. Zacks. 2 Stocks to Buy from ...The Recursion Pharmaceuticals, Inc. stock price gained 7.88% on the last trading day (Friday, 1st Dec 2023), rising from $6.85 to $7.39. During the last trading day …

Sep 22, 2023 · According to data from CNN Money, the company had 7 analysts offering 12-month price forecasts. The median target price was $14.00, with a high estimate of $35.00 and a low estimate of $9.00. The consensus among the 7 polled investment analysts was to hold the stock of Recursion Pharmaceuticals Inc. This rating had remained steady since ... Recursion Pharmaceuticals (RXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.RXRX stock does seem to be getting support at the 200-day moving average, at least for now. Wood also trimmed her holdings of Shopify in her flagship ARK Innovation ETF by just over 182,000 shares ...Find the latest Insider Activity data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.

The exchange reported a loss of $2.43 per share, compared to forecasts of a $2.52 loss per share, according to the FactSet consensus. Revenue plummeted 75% to $629.1 million, but still beat ...

RXRX Quantitative Stock Analysis - Benjamin Graham. November 18, 2023 — 01:00 pm EST. Written by John Reese for Validea ->. Below is Validea's guru fundamental report for RECURSION ...Recursion Pharmaceuticals Stock Chart and Share Price Forecast, Short-Term "RXRX" Stock Prediction for Next Days and Weeks Walletinvestor.com Recursion Pharmaceuticals Inc (RXRX) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024Nov 28, 2023 · The Baudax Bio Inc stock price gained 31.73% on the last trading day (Friday, 24th Nov 2023), rising from $0.0646 to $0.0851. During the last trading day the stock fluctuated 41.83% from a day low at $0.0600 to a day high of $0.0851. The price has fallen in 6 of the last 10 days and is down by -54.02% for this period. RXRX Stock Rips on Nvidia Investment. Shares of RXRX rallied more than 75% on Wednesday, July 12. At one point, the stock traded as high as $14.99, up 121% on the day.Created with Sketch. when trading, helping you to optimize your price and have a successful order execution. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4 ...Recursion Pharmaceuticals (RXRX 7.88%) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence …

Get the latest Recursion Pharmaceuticals, Inc RXRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Recursion Pharma may be a biotech stock, but it scored a $50 million investment from Nvidia to fund its AI technology in mid-July - making NVDA a significant stakeholder in RXRX. The partnership ...

2 days ago · RXRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more. Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Company Description. Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.how to read an earnings report. Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making ...Analyst projections state that RXRX is forecast to be at a low of $9.00 and a high of $35.00. In order for the stock price to hit the forecast high, the stock would need to plunge -435.99% from its current level, while the stock would need to crash -37.83% from its current level to reach the projected low.60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. According to the current price, Recursion Pharmaceuticals, is 42.39% away from the 52-week high. What are analysts forecasts for Recursion Pharmaceuticals, stock? The 21 analysts offering price ...Forecast . Price target. 15.71 0.00 0.00%. The 7 analysts offering 1 year price forecasts for RXRX have a max estimate of — and a min estimate of —. Analyst rating. Based on 7 analysts giving stock ratings to RXRX in the past 3 months. EPS. Annual Annual Quarterly Quarterly More MoreSee what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. RXRX's current price target is …

See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Dec 1, 2023 · Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.91) per share. Recursion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 26th, 2024 based off prior year's report dates. Read More. NVDA stock has risen 3% in July, outperforming the Nasdaq Index, and has surged 200% this year, ... RXRX). The biotech company’s stock surged over 120% following the announcement, ...Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Instagram:https://instagram. is toggle insurance legitfubo tv newsis paypal a good stock to buyis molina healthcare good insurance Find the latest Royalty Pharma plc (RPRX) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W ...The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target for the stock is $15.57, which implies that it could rise by about 120% over the next 12 months. best financial planning advisorhygh stock On Monday, RXRX stock opened at $9.12. The company’s one-year low is at $4.54 while its one-year high stands at $16.75 – indicating potential volatility in its trading range in the past year. Recursion Pharmaceuticals has a market capitalization value of $1.97 billion along with a PE ratio of -6.61 and a beta coefficient of -0.05 ... bio tech etf RXRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more.All 39 ARKG ETF Holdings. The portfolio of Cathie Wood updated daily. These are the positions, trades, and weight of all companies in her ARKG Genomic Revolution ETF. Search tickers or categories... Trader's Guide 2024 Ships December 21st.Dec 1, 2023 · RXRX Stock Overview. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.